JP2011501946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501946A5 JP2011501946A5 JP2010530235A JP2010530235A JP2011501946A5 JP 2011501946 A5 JP2011501946 A5 JP 2011501946A5 JP 2010530235 A JP2010530235 A JP 2010530235A JP 2010530235 A JP2010530235 A JP 2010530235A JP 2011501946 A5 JP2011501946 A5 JP 2011501946A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- binding protein
- variant
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 102000023732 binding proteins Human genes 0.000 claims description 38
- 108091008324 binding proteins Proteins 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 32
- 150000007523 nucleic acids Chemical group 0.000 claims description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 10
- 101710112752 Cytotoxin Proteins 0.000 claims description 9
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 9
- 239000002619 cytotoxin Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000003259 recombinant expression Methods 0.000 claims description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 7
- 101100355842 Mus musculus Rbmx gene Proteins 0.000 claims description 6
- -1 carrier Substances 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims description 4
- 108010039491 Ricin Proteins 0.000 claims description 4
- 239000012830 cancer therapeutic Substances 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 229940127121 immunoconjugate Drugs 0.000 claims description 3
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims description 2
- 101710120463 Prostate stem cell antigen Proteins 0.000 claims description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 2
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 claims description 2
- 108010084592 Saporins Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 108010049223 bryodin Proteins 0.000 claims description 2
- 239000003560 cancer drug Substances 0.000 claims description 2
- 238000012875 competitive assay Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000002872 contrast media Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 229940051026 immunotoxin Drugs 0.000 claims description 2
- 239000002596 immunotoxin Substances 0.000 claims description 2
- 230000002637 immunotoxin Effects 0.000 claims description 2
- 231100000608 immunotoxin Toxicity 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98257507P | 2007-10-25 | 2007-10-25 | |
| PCT/CA2008/001878 WO2009052628A1 (en) | 2007-10-25 | 2008-10-23 | Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011501946A JP2011501946A (ja) | 2011-01-20 |
| JP2011501946A5 true JP2011501946A5 (enExample) | 2011-12-08 |
Family
ID=40579009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530235A Pending JP2011501946A (ja) | 2007-10-25 | 2008-10-23 | 変異体ＨｎＲＮＰＧの癌関連エピトープに対する抗体およびその使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8273550B2 (enExample) |
| EP (1) | EP2215122A4 (enExample) |
| JP (1) | JP2011501946A (enExample) |
| CN (1) | CN101970498A (enExample) |
| AU (1) | AU2008316224A1 (enExample) |
| CA (1) | CA2703140A1 (enExample) |
| WO (1) | WO2009052628A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| WO2010096486A1 (en) | 2009-02-17 | 2010-08-26 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| EP2506876B1 (en) | 2009-12-02 | 2016-10-12 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| MX385451B (es) | 2013-03-15 | 2025-03-18 | Bioven 3 Ltd | Proteínas sintéticas autoensamblables. |
| RU2765242C2 (ru) | 2015-08-07 | 2022-01-27 | Имаджинаб, Инк. | Антигенсвязывающие конструкции против молекул-мишеней |
| EP3202783A1 (en) * | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| US11124579B2 (en) * | 2017-03-29 | 2021-09-21 | Agency For Science, Technology And Research | Anti oligosaccharide antibody |
| CN112292401A (zh) | 2018-03-06 | 2021-01-29 | 英凯尔生物科技有限责任公司 | 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法 |
| CA3145301A1 (en) | 2019-07-08 | 2021-01-14 | Imcare Biotech, Llc. | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
| KR20220080098A (ko) * | 2019-09-11 | 2022-06-14 | 아임케어 바이오테크, 엘엘씨. | 항-세린 프로테아제 억제제 카잘(spik) 항체의 에피토프 |
| CN113862359B (zh) * | 2021-09-30 | 2024-07-23 | 哈尔滨医科大学 | Fam13a基因转录本在评估胶质母细胞瘤患者临床预后中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6184205B1 (en) | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
| US5856136A (en) | 1996-07-03 | 1999-01-05 | Incyte Pharmaceuticals, Inc. | Human stem cell antigens |
| US6258939B1 (en) | 1997-03-10 | 2001-07-10 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
| DE19722569A1 (de) | 1997-05-28 | 1998-12-03 | Basf Ag | Statistische Propylencopolymerisate |
| US6221999B1 (en) | 1999-09-10 | 2001-04-24 | Uniroyal Chemical Company, Inc. | High resilience, high clarity polyurethane elastomer |
| US20070224201A1 (en) | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| PT1629088E (pt) * | 2003-05-30 | 2012-04-10 | Agensys Inc | Variantes de antigénio de células estaminais de próstata (psca) e subsequências das mesmas |
| JPWO2005007800A1 (ja) * | 2003-07-18 | 2007-04-12 | 持田製薬株式会社 | 抗血小板膜糖蛋白質ｖｉモノクローナル抗体 |
| MXPA06013834A (es) * | 2004-05-28 | 2007-03-01 | Agensys Inc | Anticuerpos y moleculas relacionadas que enlazan a proteinas psca. |
| US8088908B2 (en) * | 2005-05-10 | 2012-01-03 | City Of Hope | Humanized anti-prostate stem cell antigen monoclonal antibody |
-
2008
- 2008-10-23 EP EP08841782A patent/EP2215122A4/en not_active Withdrawn
- 2008-10-23 CA CA2703140A patent/CA2703140A1/en not_active Abandoned
- 2008-10-23 AU AU2008316224A patent/AU2008316224A1/en not_active Abandoned
- 2008-10-23 US US12/738,883 patent/US8273550B2/en not_active Expired - Fee Related
- 2008-10-23 CN CN2008801229913A patent/CN101970498A/zh active Pending
- 2008-10-23 WO PCT/CA2008/001878 patent/WO2009052628A1/en not_active Ceased
- 2008-10-23 JP JP2010530235A patent/JP2011501946A/ja active Pending
-
2012
- 2012-08-22 US US13/591,715 patent/US20130039931A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011501946A5 (enExample) | ||
| JP2008508903A5 (enExample) | ||
| US12037404B2 (en) | Human monoclonal antibodies against EphA4 and their use | |
| US10494435B2 (en) | Human monoclonal antibodies specific for CD22 | |
| ES2432018T3 (es) | Anticuerpos selectivos anti-hepcidina-25 y usos de los mismos | |
| JP2012515226A5 (enExample) | ||
| JP2008538289A5 (enExample) | ||
| KR20130008021A (ko) | 리실 산화효소-유사 2 (ｌｏｘｌ2)에 결합하는 항체, 및 그를 위한 사용 방법 | |
| JP2013506428A5 (enExample) | ||
| JP7658946B2 (ja) | カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法 | |
| JP2008523825A5 (enExample) | ||
| RU2007127889A (ru) | Антитела, специфичные в отношении злокачественной опухоли, и белки клеточной поверхности | |
| CN114478780B (zh) | 识别磷脂酰肌醇蛋白聚糖3多个不同表位的抗体及其应用 | |
| JP2020533955A5 (enExample) | ||
| US20200190480A1 (en) | ANTIBODIES AGAINST ASPARTYL (ASPARAGINYL) beta-HYDROXYLASE (AABH) AND METHODS OF MAKING AND USING | |
| TWI875007B (zh) | 靶向epha2之抗體及其在癌症治療中的應用 | |
| WO2013059206A2 (en) | Monospecific and bispecific human monoclonal antibodies targeting insulin-growth factor ii (igf-ii) | |
| AU2022340645A1 (en) | Anti-cd33 antibodies and uses thereof | |
| JP2022501062A (ja) | Ｅｐｎ１を標的とする抗体 | |
| HK1235692B (zh) | 针对epha4的人类单克隆抗体和其用途 | |
| HK1235692A1 (en) | Human monoclonal antibodies against epha4 and their use |